

# Chalcone Scaffold Bearing Natural Antigout Agents

DEBARSHI KAR MAHAPATRA<sup>1\*</sup>, VIVEK ASATI<sup>2</sup>, and  
SANJAY KUMAR BHARTI<sup>3</sup>

<sup>1</sup>*Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur 440037, Maharashtra, India*

<sup>2</sup>*Department of Pharmaceutical Chemistry, NRI Institute of Pharmacy, Bhopal 462021, Madhya Pradesh, India*

<sup>3</sup>*Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur 495009, Chhattisgarh, India*

*\*Corresponding author. E-mail: mahapatradebarshi@gmail.com*

---

### ABSTRACT

Gout is a form of an arthritic syndrome characterized by severe chronic pain, discomfort, swelling, and redness in the joint present in the big toe as a result of monosodium urate (MSU) crystals accumulation. This chapter focuses on the ability of the natural and semisynthetic chalcone compounds such as 3,5,2,4-tetrahydroxychalcone, 4-hydroxyderricin, hesperidin methylchalcone, isobavachalcone, okanin, polyhydroxylated chalcones, quercetin chalcone, sappanchalcone, tetrahydroxychalcone, *trans*-chalcone, xanthoangelol, xanthoangelol B, and xanthoangeleol F in expressing antigout activity by completely suppressing the active disease proliferating enzyme, xanthine oxidase (XO), reducing the pro-inflammatory components, and suppressing the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B). This chapter will provide unparalleled information of chalcone scaffold bearing natural and semisynthetic molecules having pharmacotherapeutic perspectives. However, at present, these molecules are at nascent stages and only preclinical studies have been done so far and a